Lemelson Capital chief investment officer Emmanuel Lemelson recently increased his short position in Ligand Pharmaceuticals (NYSE: LGND) after its second quarter earnings report. “Any company whose EPS is down 76 …
The MLA Amendment also amended the upfront payments to the Company of Viking capital stock. If Viking completes …
Ligand Pharmaceuticals Incorporated LGND inked a deal to acquire Crystal Bioscience ... Consequently, Ligands shares have outperformed the industry year to date. The stock has surged 36.4% compared with the industry’s gain of 14.6% …
Most companies stock price histories show random or unpredictable movements ... Symbol Company # of Reports …
Mr. John L. Higgins is Chief Executive Officer, Director of the Company. He served as Chief Financial Officer at Connetics Corporation, a specialty pharmaceutical company, since 1997, and also served as Executive Vice President, Finance …
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on LGND at https://www.zacks.com/ap/LGND
Ligand Pharmaceuticals Incorporated LGND is scheduled to report second-quarter 2016 results ... Ligand is likely to beat earnings estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks …
Recently we covered Loeb’s best performing stock picks in 2011 based on what he shared in his ... He also sold all of his Ligand Pharmaceuticals (LGND) and Northern Trust (NTRS) holdings. He didn’t make any changes in the following …